PDCD1 and non-small cell lung carcinoma: The study of ICIs for NSCLC has been extended to first-line treatment, and PD-1/PD-L1 ICI monotherapy has improved the prognosis of some patients with advanced NSCLC and become a more favorable treatment after molecular targeted therapy (Table 1).